All News

sheila Tweet
RHEUMarampa
Important things to take note of re: HBV reactivation (risk stratification and RR) when we consider therapies for our RA pts. 👇 @RheumNow #ACR20 #MedTwitter https://t.co/ZJfnZHpmfw
Janet Pope Tweet
Janetbirdope

Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ

sheila Tweet
RHEUMarampa
Liver damage is NOT an extra-articular manifestation of RA BUT the ff'g factors are associated with liver disease in RA & can complicate management👇@RheumNow #ACR20 https://t.co/RqL69iVJpC
David Liew Tweet
drdavidliew
It's only now we have choices to warfarin that we can realise the effect of vit K blockade on OA. Nested case-control (AF pts, UK primary care): warfarin has risk vs DOAC for end-stage OA (via joint replacement) aOR 1.25 esp knee aOR 1.48 @Tuhina_Neogi #ACR20 ABST0934 @RheumNow https://t.co/XVLG8kIL0W
Mrinalini Dey Tweet
DrMiniDey
Plenary session: Dr Ballal presents data showing #warfarin use incr. risk of knee/hip replacements, compared to #DOACs - Nest case-control study in UK THIN database - Risk increases w/ duration of use - Indicates need for well-powered RCT of vit K in OA Abs#0934 #ACR20 @RheumNow https://t.co/YyxDjNQEjx
Bella Mehta Tweet
bella_mehta
Amazing to see a plenary by a 1st year fellow @BU_BMC_Rheum - Vit K is important in preventing #OA progression - obs study #Warfarin has higher knee and hip replacement risk compared to #DOACs #ACR20 @RheumNow ABS#0934 https://t.co/0IUS8QvzI4
sheila Tweet
RHEUMarampa
What is refractory RA? Inability to reach #T2T goals of remission or at least LDA despite various changes of tx. "We should aim at best care for the tx of refractory RA"-Prof.Josef Smolen @RheumNow #ACR20 https://t.co/7Wxjd5t3Oi
Janet Pope Tweet
Janetbirdope
50% use septra/bactrim in SLE if immunesuppressed. I don’t use it unless if frequent serious infections or bad lungs as I am not convinced about the risk of PCP/PJP v risk of septra with adverse rxns in SLE. I await an admin database to give me the data @RheumNow #ACR20 https://t.co/3s2S9fIUVe
Eric Dein Tweet
ejdein1
Abst#0934 by Dr. Ballal at BU looks at the role of vitamin K deficiency in OA development. Warfarin use with 57% increased risk of TKA/THA compared to NOAC, though diminished when accounting for signif practice variation in these patients @Rheumnow #ACR20 https://t.co/PsESoeurKF
Dr. Rachel Tate Tweet
uptoTate
MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (domain?) response to TNFi vs IL17i. Dr. J. Ermann #ACR20 @RheumNow #ACRbest https://t.co/0ZcEIvkuMj
Eric Dein Tweet
ejdein1
Re Abs#760: Bone erosions in +CCP not predictive of development of IA. You have a pt with no synovitis, but +CCP, small bone erosion on standing foot xray. Do you treat? #ACR20 @Rheumnow
Janet Pope Tweet
Janetbirdope
Tell me what do you focus more on in virtual learning? I will try to vary my backgrounds as a virtual home yours! @RheumNow @CRASCRRheum #ACR20
sheila Tweet
RHEUMarampa
Nintedanib for RA-ILD? In the INBUILD Trial, pts on Nintedanib did better than PBO, efficacy similar among autoimmune ILDs including RA. @RheumNow #ACR20 @joanbathon https://t.co/I4AJlemIhD
Eric Dein Tweet
ejdein1
Dr Hansen at 3S008 on "Bone for the Holidays": individualize the decision for drug holidays - here are the key questions: #acr20 @Rheumnow https://t.co/lMHtYW4OzE
Dr. Antoni Chan Tweet
synovialjoints
Which Axial SpA outcome score do you use in clinic as a target to achieve? @RheumNow #ACR20
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×